Prothena Corporation plc Logo

Email this page: News Release

Prothena Reports Robust Reduction of Free Serum Alpha-Synuclein of up to 96% After Single Dose of PRX002, a Novel Protein Immunotherapy for Parkinson's Disease

For security reasons, registration is required before you can use this feature.
* Indicates required field